New guidance outlines use of first immunotherapy for children newly diagnosed with type 1 diabetes
For the first time, children ages 8 to 17 who are newly diagnosed with type 1 diabetes have access to an approved treatment that targets the underlying autoimmune disease, rather than solely managing blood sugar levels with insulin.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
A microbe-made molecule may reverse gut damage by boosting NAD levels
United Kingdom
-
Longer inhibitory connections can push simulated neural networks beyond critical tipping point
United Kingdom
-
AHA: More intensive blood pressure lowering cuts future cardiovascular risk after stroke, transient ischemic attack
United Kingdom
-
Newly identified enzyme protects growth protein in leukemia cells
United Kingdom
-
Forever chemical disturbs early development in stem cell model
United Kingdom
-
Older AI-estimated heart age linked to worse health outcomes
United Kingdom
-
Dr. King’s Lost Draft of ‘I Have a Dream’ Emerges from a Desk Drawer
United Kingdom
-
Blood NAD levels track heart disease, not aging, study of more than 1,000 adults finds
United Kingdom